Orchid Pharma gets EIR from US FDA

The Chennai facility was recently inspected by US FDA

Orchid Pharma has received Establishment Inspection Report (EIR) from the US health regulator for its Chennai facility. The company has received the EIR from the United States Food and Drug Administration (US FDA) on successful inspection closure for the post-marketing adverse drug experience reporting inspection (PADE) conducted at Nungambakkam, Chennai facility, Orchid Pharma said in a BSE filing.

The facility was inspected by US FDA in the month of June, 2017, it added. As per the US FDA, after the completion of an inspection of a facility, an EIR is issued to a company detailing inspectional findings.